Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: a CRIOGO multicentre retrospective study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      CRIOGO study group
    • Source:
      Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE
    • Publication Information:
      Publication: 1997- : London : Oxford University Press
      Original Publication: London, New York, Academic Press.
    • Subject Terms:
      Staphylococcus epidermidis*/drug effects ; Staphylococcus epidermidis*/isolation & purification ; Fluoroquinolones*/pharmacology ; Microbial Sensitivity Tests* ; Anti-Bacterial Agents*/pharmacology ; Staphylococcal Infections*/microbiology ; Staphylococcal Infections*/drug therapy; Humans ; Retrospective Studies ; Ofloxacin/pharmacology ; Levofloxacin/pharmacology ; Drug Resistance, Bacterial ; Moxifloxacin/pharmacology ; France
    • Abstract:
      Objectives: Staphylococcus epidermidis bone and joint infections (BJIs) on material are often difficult to treat. The activity of delafloxacin has not yet been studied on S. epidermidis in this context. The aim of this study was to assess its in vitro activity compared with other fluoroquinolones, against a large collection of S. epidermidis clinical strains.
      Methods: We selected 538 S. epidermidis strains isolated between January 2015 and February 2023 from six French teaching hospitals. One hundred and fifty-two strains were ofloxacin susceptible and 386 were ofloxacin resistant. Identifications were performed by MS and MICs were determined using gradient concentration strips for ofloxacin, levofloxacin, moxifloxacin and delafloxacin.
      Results: Ofloxacin-susceptible strains were susceptible to all fluoroquinolones. Resistant strains had higher MICs of all fluoroquinolones. Strains resistant to ofloxacin (89.1%) still showed susceptibility to delafloxacin when using the Staphylococcus aureus 2021 CA-SFM/EUCAST threshold of 0.25 mg/L. In contrast, only 3.9% of the ofloxacin-resistant strains remained susceptible to delafloxacin with the 0.016 mg/L S. aureus breakpoint according to CA-SFM/EUCAST guidelines in 2022. The MIC50 was 0.094 mg/L and the MIC90 was 0.38 mg/L.
      Conclusions: We showed low delafloxacin MICs for ofloxacin-susceptible S. epidermidis strains and a double population for ofloxacin-resistant strains. Despite the absence of breakpoints for S. epidermidis, delafloxacin may be an option for the treatment of complex BJI, including strains with MICs of ≤0.094 mg/L, leading to 64% susceptibility. This study underlines the importance for determining specific S. epidermidis delafloxacin breakpoints for the management of BJI on material.
      (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].)
    • Contributed Indexing:
      Investigator: P Abgueguen; M Caubrière; C Lemarie; R Chenouard; H Pailhories; A Vildy; S Ansart; L Quaesaet; E Stindel; D Tandé; C Lamoureux; A Greves; D Boutoille; R Lecomte; C Deschanvres; C Nich; V Crenn; P Bémer; S Corvec; L Ruffier d'Epenoux; A Paquin; M Grégoire; C Bourigault; B Plantard; F Cazenave-Roblot; G Le Moal; P Pries; C Plouzeau-Jayle; C Thomas; C Arvieux; M Baldeyrou; H Common; V Cattoir; S Reissier; A Méheut; L Bernard; A Lemaignen; M Lacasse; P Rosset; LR Le Nail; MF Lartigue; I Laplaige; L Chaufour
    • Accession Number:
      0 (Fluoroquinolones)
      0 (Anti-Bacterial Agents)
      6315412YVF (delafloxacin)
      A4P49JAZ9H (Ofloxacin)
      6GNT3Y5LMF (Levofloxacin)
      U188XYD42P (Moxifloxacin)
    • Publication Date:
      Date Created: 20240320 Date Completed: 20240502 Latest Revision: 20240724
    • Publication Date:
      20240725
    • Accession Number:
      10.1093/jac/dkae071
    • Accession Number:
      38507272